Validation of MRI as a biomarker in clinical trials

8 July 2021

Delivered by Dr. Hermien Kan

Dr. Hermien E. Kan is staff member of the C.J. Gorter Center for high field MRI at the Leiden Universtiy Medical Center, where her main focus is on quantitiatve MR muscle and brain in Duchenne and Becker muscular dystrophy and high field muscle MR spectroscopy. 

She started her research into MR methods of skeletal muscle in patients with facioscapulohumeral dystrophy, by performing MR imaging and phosphorous MRS to study muscle at the Radboud university Medical Center in Nijmegen. She then moved to the LUMC to work on DMD and BMD. She was a member of the TREAT-NMD network of excellence MRI working group and is a member of the scientific advisory board of the Prinses Beatrix Spierfonds. Her current research is funded by grants from the Dutch Science Foundation, the Duchenne Parent Project and the EU. She is site PI on the H2020 project BIND and co-chair of the Imaging in Neuromuscular disease conference 2021. she recently extended her research line to also include Myasthenia Gravis, where she is looking at the involvement of the extra-ocular muscles by MRI. 

 

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern